Arcadia Biosciences Book Value Per Share Growth & History (RKDA)
Arcadia Biosciences's book value per share was $3.02 for fiscal 2025.
View full Arcadia Biosciences company overviewArcadia Biosciences annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.02 | -$1.54 | −33.87% |
| 2024 | 2024-12-31 | $4.56 | -$5.43 | −54.36% |
| 2023 | 2023-12-31 | $9.99 | -$24.15 | −70.74% |
| 2022 | 2022-12-31 | $34.14 | -$21.92 | −39.10% |
| 2021 | 2021-12-31 | $56.06 | -$26.39 | −32.00% |
| 2020 | 2020-12-31 | $82.45 | $46.80 | +131.30% |
| 2019 | 2019-12-31 | $35.65 | -$71.71 | −66.80% |
| 2018 | 2018-12-31 | $107.35 | -$42.72 | −28.47% |
| 2017 | 2017-12-31 | $150.07 | -$249.10 | −62.40% |
| 2016 | 2016-12-31 | $399.18 | -$329.14 | −45.19% |
| 2015 | 2015-12-31 | $728.31 | $33,424.47 | — |
| 2014 | 2014-12-31 | -$32,696.15 | — | — |
Arcadia Biosciences quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0.29 | -$3.03 | −91.25% |
| Q1 2026 | 2026-03-31 | $1.40 | -$5.11 | −78.47% |
| Q4 2025 | 2025-12-31 | $3.02 | -$1.54 | −33.87% |
| Q3 2025 | 2025-09-30 | $3.98 | -$3.56 | −47.18% |
| Q2 2025 | 2025-06-30 | $3.32 | -$5.27 | −61.39% |
| Q1 2025 | 2025-03-31 | $6.51 | -$1.28 | −16.41% |
| Q4 2024 | 2024-12-31 | $4.56 | -$5.43 | −54.36% |
| Q3 2024 | 2024-09-30 | $7.54 | -$6.46 | −46.14% |
| Q2 2024 | 2024-06-30 | $8.59 | -$7.53 | −46.73% |
| Q1 2024 | 2024-03-31 | $7.79 | -$11.83 | −60.28% |
| Q4 2023 | 2023-12-31 | $9.99 | -$24.15 | −70.74% |
| Q3 2023 | 2023-09-30 | $13.99 | -$26.70 | −65.61% |
| Q2 2023 | 2023-06-30 | $16.12 | -$32.20 | −66.64% |
| Q1 2023 | 2023-03-31 | $19.62 | -$34.93 | −64.04% |
| Q4 2022 | 2022-12-31 | $34.14 | -$21.92 | −39.10% |
| Q3 2022 | 2022-09-30 | $40.69 | -$31.15 | −43.36% |
| Q2 2022 | 2022-06-30 | $48.33 | -$26.83 | −35.70% |
| Q1 2022 | 2022-03-31 | $54.55 | -$28.88 | −34.62% |
| Q4 2021 | 2021-12-31 | $56.06 | -$26.39 | −32.00% |
| Q3 2021 | 2021-09-30 | $71.84 | $30.19 | +72.48% |
| Q2 2021 | 2021-06-30 | $75.15 | $26.89 | +55.73% |
| Q1 2021 | 2021-03-31 | $83.43 | $32.52 | +63.87% |
| Q4 2020 | 2020-12-31 | $82.45 | $46.80 | +131.30% |
| Q3 2020 | 2020-09-30 | $41.65 | -$21.01 | −33.52% |
| Q2 2020 | 2020-06-30 | $48.26 | -$4.63 | −8.76% |
| Q1 2020 | 2020-03-31 | $50.91 | $45.61 | +860.62% |
| Q4 2019 | 2019-12-31 | $35.65 | -$71.71 | −66.80% |
| Q3 2019 | 2019-09-30 | $62.66 | -$45.59 | −42.12% |
| Q2 2019 | 2019-06-30 | $52.89 | -$15.23 | −22.36% |
| Q1 2019 | 2019-03-31 | $5.30 | -$5.45 | −50.71% |
| Q4 2018 | 2018-12-31 | $107.35 | -$42.72 | −28.47% |
| Q3 2018 | 2018-09-30 | $108.25 | -$91.68 | −45.86% |
| Q2 2018 | 2018-06-30 | $68.11 | -$208.67 | −75.39% |
| Q1 2018 | 2018-03-31 | $10.75 | -$333.72 | −96.88% |
| Q4 2017 | 2017-12-31 | $150.07 | -$249.10 | −62.40% |
| Q3 2017 | 2017-09-30 | $199.93 | -$294.88 | −59.59% |
| Q2 2017 | 2017-06-30 | $276.78 | -$287.03 | −50.91% |
| Q1 2017 | 2017-03-31 | $344.47 | -$296.94 | −46.29% |
| Q4 2016 | 2016-12-31 | $399.18 | -$329.14 | −45.19% |
| Q3 2016 | 2016-09-30 | $494.81 | -$303.40 | −38.01% |
| Q2 2016 | 2016-06-30 | $563.81 | -$315.93 | −35.91% |
| Q1 2016 | 2016-03-31 | $641.41 | $36,015.67 | — |
| Q4 2015 | 2015-12-31 | $728.31 | $33,424.47 | — |
| Q3 2015 | 2015-09-30 | $798.21 | — | — |
| Q2 2015 | 2015-06-30 | $879.75 | — | — |
| Q1 2015 | 2015-03-31 | -$35,374.26 | — | — |
| Q4 2014 | 2014-12-31 | -$32,696.15 | — | — |
Arcadia Biosciences book value per share trends
Over the last five fiscal years, Arcadia Biosciences's book value per share decreased from $82.45 to $3.02, a change of -$79.43. The latest reported quarter, Q2 2026, shows $0.29.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Arcadia Biosciences source filings ↗